Phathom Pharmaceuticals is committed to transforming the treatment landscape for people suffering from acid-related gastrointestinal (GI) disorders. Phathom’s lead clinical candidate, vonoprazan, is a potassium-competitive acid blocker (P-CAB), a novel class of medicines with the potential to address multiple unmet needs in GI medicine.